Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, including sales of the subcutaneous product daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S., as reported by J&J (JNJ) were $3.539B in the second quarter of 2025. Net trade sales were $2.017B in the U.S. and $1.521B in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Abbvie and Genmab’s Promising Study on Epcoritamab for Lymphoma: A Financial Perspective
- Genmab’s Tisotumab Vedotin Study: A Potential Game-Changer in Cervical Cancer Treatment
- Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment
- AbbVie and Genmab’s Epcoritamab Trial: A Promising Update for B-NHL Treatment
- Genmab’s Phase 3 Trial: A Potential Game-Changer for Lung Cancer Treatment?